Growth N. V. Biotech Sells 25,100 Shares of ESSA Pharma Inc. (NASDAQ:EPIX) Stock

ESSA Pharma Inc. (NASDAQ:EPIXGet Rating) (TSE:EPI) major shareholder Growth N. V. Biotech sold 25,100 shares of the business’s stock in a transaction dated Wednesday, April 27th. The shares were sold at an average price of $5.85, for a total value of $146,835.00. Following the completion of the sale, the insider now directly owns 4,990,714 shares of the company’s stock, valued at $29,195,676.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

NASDAQ:EPIX opened at $5.88 on Friday. The firm has a market capitalization of $258.81 million, a PE ratio of -6.00 and a beta of 1.64. The stock has a 50 day moving average of $7.09 and a 200-day moving average of $9.66. ESSA Pharma Inc. has a 52 week low of $5.47 and a 52 week high of $36.00.

ESSA Pharma (NASDAQ:EPIXGet Rating) (TSE:EPI) last posted its earnings results on Thursday, February 3rd. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.02. On average, sell-side analysts forecast that ESSA Pharma Inc. will post -1.07 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alta Wealth Advisors LLC acquired a new stake in ESSA Pharma in the first quarter worth approximately $70,000. Values First Advisors Inc. acquired a new stake in ESSA Pharma in the fourth quarter worth approximately $194,000. BlackRock Inc. lifted its position in ESSA Pharma by 4.9% in the fourth quarter. BlackRock Inc. now owns 85,638 shares of the company’s stock worth $1,217,000 after purchasing an additional 4,000 shares during the period. Woodline Partners LP lifted its position in ESSA Pharma by 286.6% in the fourth quarter. Woodline Partners LP now owns 684,247 shares of the company’s stock worth $9,716,000 after purchasing an additional 507,239 shares during the period. Finally, California State Teachers Retirement System lifted its position in ESSA Pharma by 11.4% in the fourth quarter. California State Teachers Retirement System now owns 20,427 shares of the company’s stock worth $290,000 after purchasing an additional 2,091 shares during the period. Hedge funds and other institutional investors own 89.80% of the company’s stock.

About ESSA Pharma (Get Rating)

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer.

See Also

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.